MedTrace Logo

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2025-09-17

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.

Conditions

  • Hyperhidrosis

Interventions

DRUG

Dose 1 of glycopyrrolate, 2.0% QD

Dose 1 of glycopyrrolate Topical Wipes

DRUG

Dose 2 of glycopyrrolate, 3.0% QD

Dose 2 of glycopyrrolate Topical Wipes

DRUG

Dose 1 of glycopyrronium, 2.5% QD

Dose 1 of glycopyrronium Topical Wipes

DRUG

Dose 2 of glycopyrronium, 3.75% QD

Dose 2 of glycopyrronium Topical Wipes

OTHER

Vehicle

Vehicle Topical Wipes

Sponsors & Collaborators

  • Journey Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Lynne M. Deans, MT · Dermira, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129660 on ClinicalTrials.gov